Difloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Difloxacin
DrugBank Accession Number
DB11511
Background

Difloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration. However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials.

Type
Small Molecule
Groups
Vet approved
Structure
Weight
Average: 399.398
Monoisotopic: 399.13944781
Chemical Formula
C21H19F2N3O3
Synonyms
  • Difloxacin
  • difloxacino

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Difloxacin.
AceclofenacAceclofenac may increase the neuroexcitatory activities of Difloxacin.
AcemetacinAcemetacin may increase the neuroexcitatory activities of Difloxacin.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be increased when used in combination with Difloxacin.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Difloxacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Difloxacin hydrochlorideXJ0260HJ0O91296-86-5JFMGBGLSDVIOHL-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylquinolines. These are heterocyclic compounds containing a quinoline moiety substituted with a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Phenylquinolines
Direct Parent
Phenylquinolines
Alternative Parents
Quinoline carboxylic acids / Fluoroquinolones / N-arylpiperazines / Aminoquinolines and derivatives / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Fluorobenzenes
show 14 more
Substituents
1,4-diazinane / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines (CHEBI:4537)
Affected organisms
Not Available

Chemical Identifiers

UNII
5Z7OO9FNFD
CAS number
98106-17-3
InChI Key
NOCJXYPHIIZEHN-UHFFFAOYSA-N
InChI
InChI=1S/C21H19F2N3O3/c1-24-6-8-25(9-7-24)19-11-18-15(10-17(19)23)20(27)16(21(28)29)12-26(18)14-4-2-13(22)3-5-14/h2-5,10-12H,6-9H2,1H3,(H,28,29)
IUPAC Name
6-fluoro-1-(4-fluorophenyl)-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
CN1CCN(CC1)C1=C(F)C=C2C(=C1)N(C=C(C(O)=O)C2=O)C1=CC=C(F)C=C1

References

General References
  1. Atef M, el-Banna HA, Abd El-Aty AM, Goudah A: Pharmacokinetics of difloxacin in goats. Dtsch Tierarztl Wochenschr. 2002 Jul;109(7):320-3. [Article]
  2. Prabhakaran D, Sukul P, Lamshoft M, Maheswari MA, Zuhlke S, Spiteller M: Photolysis of difloxacin and sarafloxacin in aqueous systems. Chemosphere. 2009 Oct;77(6):739-46. doi: 10.1016/j.chemosphere.2009.08.031. Epub 2009 Sep 13. [Article]
  3. Olchowy TW, TerHune TN, Herrick RL: Efficacy of difloxacin in calves experimentally infected with Mannheimia haemolytica. Am J Vet Res. 2000 Jun;61(6):710-3. [Article]
  4. Granneman GR, Snyder KM, Shu VS: Difloxacin metabolism and pharmacokinetics in humans after single oral doses. Antimicrob Agents Chemother. 1986 Nov;30(5):689-93. [Article]
  5. Mavrogianni VS, Fthenakis GC: Efficacy of difloxacin against respiratory infections of lambs. J Vet Pharmacol Ther. 2005 Jun;28(3):325-8. [Article]
  6. van den Hoven R, Wagenaar JA, Walker RD: In vitro activity of difloxacin against canine bacterial isolates. J Vet Diagn Invest. 2000 May;12(3):218-23. [Article]
  7. Sukul P, Lamshoft M, Kusari S, Zuhlke S, Spiteller M: Metabolism and excretion kinetics of 14C-labeled and non-labeled difloxacin in pigs after oral administration, and antimicrobial activity of manure containing difloxacin and its metabolites. Environ Res. 2009 Apr;109(3):225-31. doi: 10.1016/j.envres.2008.12.007. Epub 2009 Jan 31. [Article]
  8. Fernandes PB, Chu DT, Bower RR, Jarvis KP, Ramer NR, Shipkowitz N: In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. Antimicrob Agents Chemother. 1986 Feb;29(2):201-8. [Article]
  9. Bansal MB, Thadepalli H: Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitro. Antimicrob Agents Chemother. 1987 Apr;31(4):619-21. [Article]
  10. Lamshoft M, Sukul P, Zuhlke S, Spiteller M: Behaviour of (14)C-sulfadiazine and (14)C-difloxacin during manure storage. Sci Total Environ. 2010 Mar 1;408(7):1563-8. doi: 10.1016/j.scitotenv.2009.12.010. Epub 2009 Dec 21. [Article]
KEGG Drug
D07828
KEGG Compound
C11234
ChemSpider
50725
ChEBI
4537
ChEMBL
CHEMBL6259
ZINC
ZINC000004099034
Wikipedia
Difloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.126 mg/mLALOGPS
logP1.16ALOGPS
logP2.36Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.64Chemaxon
pKa (Strongest Basic)6.45Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area64.09 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity105.19 m3·mol-1Chemaxon
Polarizability39.25 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0013900000-2f0533cdd6722829bba3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0001900000-39559042c9c17f22b056
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0003900000-eeb11a494a85c69cc39d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0037900000-24e9d598116abf61643a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0zfs-0196200000-7e5e7b2e464e8cee97c2
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0000900000-eb816b59e49880b716fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0000900000-45746cb99dbc2c1e8a5a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0pc0-0019500000-7c3ad675ae6a4c089ac6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6t-1097400000-e4426c10a3fca116fd72
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052b-1192000000-dcd995c8456a1135ae84
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a6r-2390000000-790df0725e0d72ae05b4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-2590000000-91ae82904bc16c72ce22
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-056r-3970000000-3d9a266fce5e4c244a56
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a7i-4930000000-6b3e52ca9dd7c42c65ee
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a7i-7910000000-6721a1b8ea16086eaca1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ue9-0008900000-27d9ce0abe02245bee9a
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0009000000-2c47aef01de9c90a7147
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0009200000-450e008495cd87ae5fb3
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0009000000-9d05b0705e6cd02395df
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fdo-1009000000-ba12008c2e791efa636a
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0039000000-13b7e998660c1db18a56
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-193.9723
predicted
DeepCCS 1.0 (2019)
[M+H]+196.33029
predicted
DeepCCS 1.0 (2019)
[M+Na]+203.06143
predicted
DeepCCS 1.0 (2019)

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
Curator comments
This drug is a quinolone derivative, and these agents are known to inhibit CYP1A2.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Fuhr U, Anders EM, Mahr G, Sorgel F, Staib AH: Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Munro AW: Cytochrome P450 1A1 opens up to new substrates. J Biol Chem. 2018 Dec 14;293(50):19211-19212. doi: 10.1074/jbc.H118.006715. Epub 2018 Dec 14. [Article]

Drug created at February 26, 2016 17:28 / Updated at February 21, 2021 18:53